Monoclonal Gammopathy of Undetermined Significance (MGUS)

MGUS is defined by the following 3 criteria:

• A serum monoclonal protein <30 g/L
• Clonal bone marrow plasma cells <10%
• Absence of end organ damage that can be attributed to the plasma cell proliferative disorder

Annually, around 1% of people with MGUS go on to develop Multiple Myeloma (MM) or a related malignancy.

International Guidelines recommend MGUS patients should be risk stratified at diagnosis to optimise counselling and follow-up.

In combination with other laboratory tests, Freelite serum free light chain (FLC) assay identifies patients at low risk of progression (~40%). This saves time, money and patient discomfort, as fewer clinic visits and tests are needed.

Hevylite laboratory tests improve patient risk stratification and can help predict progression from MGUS to MM, or a related condition.